SEC Form 4 · accession 0001209191-18-001889
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Malcolm Lloyd-Smith
Officer — Chief Regulatory Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2018 | M | 18,084 | $15.45 | A | 31,101 | D | |
| Common StockF2 | Jan 2, 2018 | S | 18,084 | $77.5173 | D | 13,017 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF3 | $15.45 | Jan 2, 2018 | M | 18,084 | D | — | Oct 1, 2024 | Common Stock | 18,084 | 18,956 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.00 to $79.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Represents option which vests 1/4 upon anniversary of grant (10/1/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 10/1/2018.